Canada markets close in 2 hours 52 minutes

BioSyent Inc. (RX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
7.98-0.02 (-0.25%)
As of 11:08AM EDT. Market open.
Full screen
Loading interactive chart...
  • GlobeNewswire

    BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

    MISSISSAUGA, Ontario, Aug. 16, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2022 on Tuesday, August 23, 2022 after market hours. A presentation on the Company’s second quarter and first half 2022 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange u

  • Simply Wall St.

    BioSyent (CVE:RX) shareholders have earned a 6.8% CAGR over the last three years

    BioSyent Inc. ( CVE:RX ) shareholders might be concerned after seeing the share price drop 17% in the last quarter. In...

  • GlobeNewswire

    BioSyent Releases Financial Results for Q1 2022

    MISSISSAUGA, Ontario, May 18, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2022. Key highlights include: First quarter (Q1) 2022 Net Revenues of $7,037,411 decreased by 5% versus Q1 2021Q1 2022 Net Revenues from continuing brands (excluding discontinued Aguettant System® and Cysview® brands) decreased by 0% versus Q1 2021Q1 2022 Canadian Pharmaceutical Net Revenues of $6,318,884 increased by 1% vers